You are viewing the site in preview mode

Skip to main content

Table 3 Helicobacter pylori eradication rates in the ALEB therapy subgroup, combined AFEB therapy subgroup, and LBQT group

From: Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study

Eradication rate ALEB therapy subgroup (n = 51) Combined AFEB therapy subgroup (n = 131) LBQT group (n = 182)
ITT analysis 44/51 (86.3%) 119/131 (90.8%) 118/182 (64.8%)
PP analysis 44/50 (88.0%) 119/129 (92.2%) 118/174 (67.8%)
  1. ALEB (susceptibility-guided therapy) amoxicillin + levofloxacin + esomeprazole + colloidal bismuth pectin, LBQT levofloxacin‐ and bismuth-based quadruple therapy not guided by antibiotic susceptibility, amoxicillin + levofloxacin + esomeprazole + colloidal bismuth pectin, AFEB amoxicillin + furazolidone + esomeprazole + colloidal bismuth pectin, ITT intention‐to‐treat, PP per protocol
Back to article page

Gut Pathogens

ISSN: 1757-4749